Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyanocobalamin + salcaprozate sodium is an oral combination formulated to improve vitamin B12 (cyanocobalamin) absorption using the absorption enhancer salcaprozate sodium (also known as SNAC). Salcaprozate sodium facilitates the transport of vitamin B12 across the gastric lining, significantly enhancing its bioavailability relative to standard oral cyanocobalamin. This formulation was designed particularly for the treatment of vitamin B12 deficiency, especially in patients with malabsorption syndromes. It is classified as a "medical food" rather than a conventional pharmaceutical drug, providing pharmacokinetic and efficacy profiles that approach those of injectable B12, with similar safety. The combination formulation was developed by Emisphere Technologies and marketed under the brand name Eligen B12[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyanocobalamin + salcaprozate sodium.